A recombinant canine distemper virus expressing a modified rabies virus glycoprotein induces immune responses in mice

Virus Genes ◽  
2015 ◽  
Vol 50 (3) ◽  
pp. 434-441 ◽  
Author(s):  
Zhili Li ◽  
Jigui Wang ◽  
Daoli Yuan ◽  
Shuang Wang ◽  
Jiazeng Sun ◽  
...  
Vaccine ◽  
2008 ◽  
Vol 26 (51) ◽  
pp. 6592-6601 ◽  
Author(s):  
Sonal Saxena ◽  
Shyam S. Dahiya ◽  
Arvind A. Sonwane ◽  
Chhabi Lal Patel ◽  
Mohini Saini ◽  
...  

2017 ◽  
Vol 91 (8) ◽  
Author(s):  
Renata da Fontoura Budaszewski ◽  
Andrew Hudacek ◽  
Bevan Sawatsky ◽  
Beate Krämer ◽  
Xiangping Yin ◽  
...  

ABSTRACT The development of multivalent vaccines is an attractive methodology for the simultaneous prevention of several infectious diseases in vulnerable populations. Both canine distemper virus (CDV) and rabies virus (RABV) cause lethal disease in wild and domestic carnivores. While RABV vaccines are inactivated, the live-attenuated CDV vaccines retain residual virulence for highly susceptible wildlife species. In this study, we developed recombinant bivalent vaccine candidates based on recombinant vaccine strain rabies virus particles, which concurrently display the protective CDV and RABV glycoprotein antigens. The recombinant viruses replicated to near-wild-type titers, and the heterologous glycoproteins were efficiently expressed and incorporated in the viral particles. Immunization of ferrets with beta-propiolactone-inactivated recombinant virus particles elicited protective RABV antibody titers, and animals immunized with a combination of CDV attachment protein- and fusion protein-expressing recombinant viruses were protected from lethal CDV challenge. However, animals that were immunized with only a RABV expressing the attachment protein of CDV vaccine strain Onderstepoort succumbed to infection with a more recent wild-type strain, indicating that immune responses to the more conserved fusion protein contribute to protection against heterologous CDV strains. IMPORTANCE Rabies virus and canine distemper virus (CDV) cause high mortality rates and death in many carnivores. While rabies vaccines are inactivated and thus have an excellent safety profile and high stability, live-attenuated CDV vaccines can retain residual virulence in highly susceptible species. Here we generated recombinant inactivated rabies viruses that carry one of the CDV glycoproteins on their surface. Ferrets immunized twice with a mix of recombinant rabies viruses carrying the CDV fusion and attachment glycoproteins were protected from lethal CDV challenge, whereas all animals that received recombinant rabies viruses carrying only the CDV attachment protein according to the same immunization scheme died. Irrespective of the CDV antigens used, all animals developed protective titers against rabies virus, illustrating that a bivalent rabies virus-based vaccine against CDV induces protective immune responses against both pathogens.


2009 ◽  
Vol 136 (1-2) ◽  
pp. 36-44 ◽  
Author(s):  
Sonal Saxena ◽  
Arvind A. Sonwane ◽  
Shyam S. Dahiya ◽  
Chhabi Lal Patel ◽  
Mohini Saini ◽  
...  

2021 ◽  
Author(s):  
Heather M Callaway ◽  
Dawid Zyla ◽  
Kathryn M Hastie ◽  
Ruben Diaz Avalos ◽  
Alyssa Agarwal ◽  
...  

Rabies infection is nearly 100% lethal if untreated and kills over 50,000 people annually, many of them children. Existing rabies vaccines target the rabies virus glycoprotein (RABV-G) but generate short-lived immune responses, likely because the protein is heterogeneous under physiological conditions. Here, we report the 3.39Å cryo-EM structure of trimeric, pre-fusion RABV-G complexed with RVA122, a potently neutralizing human antibody. RVA122 binds to a quaternary epitope at the top of RABV-G, bridging domains and stabilizing RABV-G protomers in a prefusion state. RABV-G trimerization involves side-to-side interactions between the central α-helix and adjacent loops, rather than contacts between central helices, and interactions among the fusion loops at the glycoprotein base. These results provide a basis to develop improved rabies vaccines based on RABV-G stabilized in the prefusion conformation.


Virology ◽  
2006 ◽  
Vol 353 (2) ◽  
pp. 344-356 ◽  
Author(s):  
Mary Ellen Smith ◽  
Martin Koser ◽  
Sa Xiao ◽  
Catherine Siler ◽  
James P. McGettigan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document